Aditxt Inc. has announced that its subsidiary, Pearsanta, Inc., has been invited to submit a full proposal for the U.S. Department of Defense’s OCRP Pilot Award. This opportunity follows a favorable review of Pearsanta’s pre-proposal, highlighting the scientific merit and innovation of its Mitomic(R) Ovarian Test (MOT(TM)). The test is a novel blood-based diagnostic designed for the early detection of ovarian cancer, a critical advancement given the disease's often late-stage diagnosis.
The grant, which could provide up to $350,000 over two years, would support the validation of the MOT(TM) in a multi-center clinical study and prepare for its commercial launch as a laboratory-developed test. This development represents a significant step forward in the fight against ovarian cancer, offering hope for earlier detection and improved outcomes for patients. The invitation to submit a full proposal indicates that the Department of Defense recognizes the potential impact of this technology in addressing a critical healthcare need.
Aditxt Inc. operates as a social innovation platform focused on advancing health technologies. Through its ecosystem of research institutions, industry partners, and shareholders, Aditxt aims to accelerate the development and deployment of innovative health solutions. The company’s current programs are centered on immune health and precision health, with plans to expand into public health and women’s health through strategic agreements with Appili Therapeutics Inc. and Evofem. This grant opportunity aligns directly with the company's strategic focus on women’s health and precision diagnostics.
The implications of this announcement are substantial for both medical innovation and patient care. Ovarian cancer is frequently diagnosed at advanced stages when treatment options are limited and survival rates are lower. A reliable, early-detection blood test could transform clinical practice by enabling earlier intervention. Successful validation through the proposed multi-center study could pave the way for regulatory approval and widespread clinical adoption. For more information on Aditxt Inc. and its initiatives, visit https://www.Aditxt.com.
The Department of Defense’s OCRP Pilot Award program specifically funds high-impact, innovative research that addresses critical gaps in ovarian cancer detection and treatment. The potential funding of $350,000 would provide crucial resources for the rigorous clinical validation required to demonstrate the test’s efficacy and reliability. This validation phase is essential for building clinical confidence and meeting regulatory standards for laboratory-developed tests. The commercial launch of MOT(TM) as a laboratory-developed test would make this technology available to patients through specialized diagnostic laboratories.
This development matters because it addresses a persistent challenge in oncology. Early detection of ovarian cancer has remained elusive despite decades of research, contributing to its high mortality rate. The Mitomic Ovarian Test represents a novel approach that could shift the diagnostic paradigm. Furthermore, the involvement of the Department of Defense underscores the national importance of advancing ovarian cancer research, as the program also addresses health concerns affecting military personnel and veterans. The grant would not only fund validation studies but also accelerate the timeline for bringing this potentially life-saving technology to market.
